Buy Quazepam (Doral) Cas 36735-22-5

Quazepam, sold under the brand name Doral among others, is a relatively long-acting benzodiazepine derivative drug developed by the Schering Corporation in the 1970s.^[1] Quazepam is used for the treatment of insomnia, including sleep induction and sleep maintenance.^[2] Quazepam induces impairment of motor function and has relatively (and uniquely) selective hypnotic and anticonvulsant properties with considerably less overdose potential than other benzodiazepines (due to its novel receptor-subtype selectivity).^[3][4] Quazepam is an effective hypnotic which induces and maintains sleep without disruption of the sleep architecture.^[5]

It was patented in 1970 and came into medical use in 1985.^[6]

Quazepam is used for short-term treatment of insomnia related to sleep induction or sleep maintenance problems and has demonstrated superiority over other benzodiazepines, such as temazepam. It had a lower incidence of side effects than temazepam, including less sedation, amnesia, and motor impairment.^{[7][8][9][10]} Usual dosage is 7.5 to 15 mg orally at bedtime.^[11]

Quazepam is effective as a premedication prior to surgery.^[12]

Quazepam has fewer side effects than other benzodiazepines and less potential to induce tolerance and rebound effects.^[13][14] There is significantly less potential for quazepam to induce respiratory depression or to adversely affect motor coordination than other benzodiazepines.^[15] The different side effect profile of quazepam may be due to its more selective binding profile to type 1 benzodiazepine receptors.^[16][17]

• Ataxia^[18]
• Daytime somnolence^[19]
• Hypokinesia^[20]
• Cognitive and performance impairments^[21]

In September 2020, the U.S. Food and Drug Administration (FDA) required the boxed warning be updated for all benzodiazepine medicines to describe the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions consistently across all the medicines in the class.^[22]

Tolerance may occur to quazepam, but more slowly than seen with other benzodiazepines such as triazolam.^[23] Quazepam causes significantly less drug tolerance and withdrawal symptoms including less rebound insomnia upon discontinuation compared to other benzodiazepines.^{[24][25][26][27]} Quazepam may cause less rebound effects than other type1 benzodiazepine receptor selective nonbenzodiazepine drugs due to its longer half-life.^[28] Short-acting hypnotics often cause next-day rebound anxiety. Quazepam, due to its pharmacological profile, does not cause next-day rebound withdrawal effects during treatment.^[29]